Literature DB >> 15459403

Modelling the healthcare costs of an opportunistic chlamydia screening programme.

E J Adams1, D S LaMontagne, A R Johnston, J M Pimenta, K A Fenton, W J Edmunds.   

Abstract

OBJECTIVES: To estimate the average cost per screening offer, cost per testing episode and cost per chlamydia positive episode for an opportunistic chlamydia screening programme (including partner management), and to explore the uncertainty of parameter assumptions, based on the costs to the healthcare system.
METHODS: A decision tree was constructed and parameterised using empirical data from a chlamydia screening pilot study and other sources. The model was run using baseline data from the pilot, and univariate and multivariate sensitivity analyses were conducted.
RESULTS: The total estimated cost for offering screening over 12 months to 33,215 females aged 16-24 was 493,412 pounds . The average cost (with partner management) was 14.88 pounds per screening offer (90% credibility interval (CI) 10.34 to 18.56), 21.83 pounds per testing episode (90% CI 18.16 to 24.20), and 38.36 pounds per positive episode (90% CI 33.97 to 42.25). The proportion of individuals accepting screening, the clinician (general practitioner/nurse) time and their relative involvement in discussing screening, the test cost, the time to notify patients of their results, and the receptionist time recruiting patients had the greatest impact on the outcomes in both the univariate and multivariate sensitivity analyses.
CONCLUSIONS: Results from this costing study may be used to inform resource allocation for current and future chlamydia screening programme implementation.

Entities:  

Mesh:

Year:  2004        PMID: 15459403      PMCID: PMC1744903          DOI: 10.1136/sti.2004.009654

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  12 in total

1.  Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach.

Authors:  R Welte; M Kretzschmar; R Leidl; A van den Hoek; J C Jager; M J Postma
Journal:  Sex Transm Dis       Date:  2000-10       Impact factor: 2.830

2.  Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy.

Authors:  J M Marrazzo; C L Celum; S D Hillis; D Fine; S DeLisle; H H Handsfield
Journal:  Sex Transm Dis       Date:  1997-03       Impact factor: 2.830

3.  Chlamydia positivity versus prevalence. What's the difference?

Authors:  L W Dicker; D J Mosure; W C Levine
Journal:  Sex Transm Dis       Date:  1998-05       Impact factor: 2.830

4.  Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.

Authors:  M R Howell; T C Quinn; C A Gaydos
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

5.  Partner notification to prevent pelvic inflammatory disease in women. Cost-effectiveness of two strategies.

Authors:  M R Howell; W J Kassler; A Haddix
Journal:  Sex Transm Dis       Date:  1997-05       Impact factor: 2.830

6.  Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis.

Authors:  M J Postma; R Welte; J A van den Hoek; G J van Doornum; H C Jager; R A Coutinho
Journal:  Value Health       Date:  2001 May-Jun       Impact factor: 5.725

7.  Opportunistic screening for genital chlamydial infection. II: prevalence among healthcare attenders, outcome, and evaluation of positive cases.

Authors:  J M Pimenta; M Catchpole; P A Rogers; J Hopwood; S Randall; H Mallinson; E Perkins; N Jackson; C Carlisle; G Hewitt; G Underhill; T Gleave; L McLean; A Ghosh; J Tobin; V Harindra
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

8.  Opportunistic screening for genital chlamydial infection. I: acceptability of urine testing in primary and secondary healthcare settings.

Authors:  J M Pimenta; M Catchpole; P A Rogers; E Perkins; N Jackson; C Carlisle; S Randall; J Hopwood; G Hewitt; G Underhill; H Mallinson; L McLean; T Gleave; J Tobin; V Harindra; A Ghosh
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

9.  Decreased prevalence of Chlamydia trachomatis infection associated with a selective screening program in family planning clinics in Wisconsin.

Authors:  D G Addiss; M L Vaughn; D Ludka; J Pfister; J P Davis
Journal:  Sex Transm Dis       Date:  1993 Jan-Feb       Impact factor: 2.830

10.  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.

Authors:  D Scholes; A Stergachis; F E Heidrich; H Andrilla; K K Holmes; W E Stamm
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  9 in total

1.  Healthcare and patient costs of a proactive chlamydia screening programme: the Chlamydia Screening Studies project.

Authors:  Suzanne Robinson; Tracy Roberts; Pelham Barton; Stirling Bryan; John Macleod; Anne McCarthy; Matthias Egger; Emma Sanford; Nicola Low
Journal:  Sex Transm Infect       Date:  2007-01-17       Impact factor: 3.519

Review 2.  One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations.

Authors:  L Barham; D Lewis; N Latimer
Journal:  Sex Transm Infect       Date:  2007-07-11       Impact factor: 3.519

3.  Focus on Chlamydia.

Authors:  Nicola Low; Helen Ward
Journal:  Sex Transm Infect       Date:  2007-07       Impact factor: 3.519

Review 4.  Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.

Authors:  T E Roberts; S Robinson; P Barton; S Bryan; N Low
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC.

Authors:  Rachel Binet; Anthony T Maurelli
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Partner notification of chlamydia infection in primary care: randomised controlled trial and analysis of resource use.

Authors:  Nicola Low; Anne McCarthy; Tracy E Roberts; Mia Huengsberg; Emma Sanford; Jonathan A C Sterne; John Macleod; Chris Salisbury; Karl Pye; Aisha Holloway; Andrea Morcom; Rita Patel; Suzanne M Robinson; Paddy Horner; Pelham M Barton; Matthias Egger
Journal:  BMJ       Date:  2005-12-15

7.  The cost effectiveness of opportunistic chlamydia screening in England.

Authors:  Elisabeth J Adams; Katherine M E Turner; W John Edmunds
Journal:  Sex Transm Infect       Date:  2007-07       Impact factor: 3.519

8.  Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project.

Authors:  Tracy E Roberts; Suzanne Robinson; Pelham M Barton; Stirling Bryan; Anne McCarthy; John Macleod; Matthias Egger; Nicola Low
Journal:  BMJ       Date:  2007-07-26

9.  Analysis of laboratory testing results collected in an enhanced chlamydia surveillance system in Australia, 2008-2010.

Authors:  Wayne Dimech; Megan S C Lim; Caroline Van Gemert; Rebecca Guy; Douglas Boyle; Basil Donovan; Margaret Hellard
Journal:  BMC Infect Dis       Date:  2014-06-12       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.